Efalizumab-induced autoimmune pancytopenia

W L Tom1, M D Miller, M Y Hurley

  • 1Department of Dermatology, Saint Louis University School of Medicine, 1402 South Grand Blvd, MO 63104, USA.

Efalizumab is a recombinant, humanized monoclonal anti-CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Immune-mediated thrombocytopenia and anaemia have previously been reported with this therapy. We describe the first case of immune-mediated pancytopenia in a patient treated with efalizumab. Close monitoring of all blood cell counts is warranted in light of this case.